Vincristine clinical trials
Also written Oncovin, VCR, Vincrex and NSC-67574.
Includes 12 studies of Vincristine Sulfate Liposome and 5 studies of Vincristine Liposomal.
How each study uses Vincristine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Vincristine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Jul 1963 · ONCOVIN · NDA 014103 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
334 studies that test it; most in 2004 (25); 1 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1992 | 2 |
| 1993 | 2 |
| 1994 | 3 |
| 1995 | 6 |
| 1996 | 12 |
| 1997 | 6 |
| 1998 | 18 |
| 1999 | 9 |
| 2000 | 9 |
| 2001 | 10 |
| 2002 | 12 |
| 2003 | 18 |
| 2004 | 25 |
| 2005 | 11 |
| 2006 | 11 |
| 2007 | 16 |
| 2008 | 13 |
| 2009 | 14 |
| 2010 | 7 |
| 2011 | 9 |
| 2012 | 9 |
| 2013 | 9 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 13 |
| 2017 | 7 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 10 |
| 2021 | 9 |
| 2022 | 8 |
| 2023 | 8 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 315
Children's Oncology Group (52) · National Cancer Institute (NCI) (29) · St. Jude Children's Research Hospital (22) · M.D. Anderson Cancer Center (15) · Memorial Sloan Kettering Cancer Center (8) · SWOG Cancer Research Network (7) · Alliance for Clinical Trials in Oncology (6) · H. Lee Moffitt Cancer Center and Research Institute (6)
Often tested with
Tested in the same studies.
Cyclophosphamide (202) · Doxorubicin (155) · Prednisone (122) · Etoposide (107) · Methotrexate (74) · Rituximab (63) · Cytarabine (63) · Dexamethasone (63)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 14 phase 3 studies under way
Vincristine is the comparator. A study of two new drugs counts under both.
- 3Lenalidomide · The Lymphoma Academic Research Organisation, Ruijin Hospital · next primary completion Sep 2027
- 2Selumetinib sulfate · National Cancer Institute (NCI) · next primary completion Dec 2027
- 2AZD 6244 · National Cancer Institute (NCI) · next primary completion Dec 2027
- 2Mosunetuzumab · The Lymphoma Academic Research Organisation · next primary completion Sep 2027
- 2Axicabtagene ciloleucel · Kite, A Gilead Company · next primary completion Oct 2030
- 1Brentuximab Vedotin · University of Cologne
- 1Dacarbazine · University of Cologne
- 1Dexamethasone · University of Cologne
Reaching primary completion within a year · 14, 7 in phase 3
Studies that test Vincristine, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Dec 2026Paediatric Hepatic International Tumour TrialPhase 3 · University of Birmingham
- Dec 2026Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)Phase 3 · Children's Cancer Group, China
- Dec 2026First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)Phase 3 · State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
- Jun 2027A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Phase 3 · Genmab
- Jun 2027Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPhase 3 · National Cancer Institute (NCI)
- Oct 2027PPI Versus Histamine Antagnists as Adjuvant to ChemotherapyPhase 3 · Sherief Abd-Elsalam
- Dec 2026A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell LymphomaPhase 2 · University of Rochester
- Jan 2027Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Phase 2 · St. Jude Children's Research Hospital
- Apr 2027Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Phase 2 · Jennifer Amengual
Studies
Open first, then newest update. How each study uses Vincristine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 344
- Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaRecruitingPhase 4St. Jude Children's Research HospitalNCT06289673Written as VincristineHow we know
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as CHOPHow we know
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaRecruitingPhase 2/3National Cancer Institute (NCI)NCT07724457Written as VincristineHow we know
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Vincristine SulfateHow we know
- The CARDIOPROTECT TrialNot yet recruitingPhase 2Beth Israel Deaconess Medical CenterNCT07654426Written as VincristineHow we know
- A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell LymphomaRecruitingPhase 2University of RochesterNCT03758989Written as VincristineHow we know
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07194044Written as VincristineHow we know
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed MedulloblastomaRecruitingPhase 2St. Jude Children's Research HospitalNCT05535166Written as VincristineHow we know
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06528496Written as VincristineHow we know
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)RecruitingPhase 3Children's Oncology GroupNCT06401330Written as VincristineHow we know
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as Vincristine SulfateHow we know
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTRecruitingPhase 2Children's Oncology GroupNCT04322318Written as VincristineHow we know
- Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary BlastomaRecruitingPhase 3Children's Oncology GroupNCT06647953Written as VincristineHow we know
- ALL Backbone in AYAsRecruitingPhase 2Dana-Farber Cancer InstituteNCT07227584Written as VincristineHow we know
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as VincristineHow we know
- Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in ChildrenRecruitingPhase 2Hee Young JuNCT06099366Written as induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal MethotrexateHow we know
- Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07643103Written as VincristineHow we know
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingPhase 2University of ChicagoNCT04747912Written as VincristineHow we know
- Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsRecruitingPhase 2/3Children's Cancer Group, ChinaNCT07168980Written as Prednisone,Vincristine, CyclophosphamideHow we know
- Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)RecruitingPhase 2Jennifer AmengualNCT06954805Written as VincristineHow we know
See all 344 studies that test Vincristine →
Given beside what is tested · 447 — Vincristine is usual care or a partner of the new treatment
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingPhase 1National Cancer Institute (NCI)NCT04301076Written as Vincristine SulfateHow we know
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as VincristineHow we know
- BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia PatientsRecruitingPhase 2Ruijin HospitalNCT07301138Written as VincristineHow we know
- Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK StudyRecruitingPhase 2AIDS Malignancy ConsortiumNCT07662928Written as VincristineHow we know
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT06023641Written as VincristineHow we know
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07634471Written as VincristineHow we know
- Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsRecruitingPhase 1/2Milton S. Hershey Medical CenterNCT06541262Written as VincristineHow we know
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Written as Vincristine SulfateHow we know
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07387926Written as VincristineHow we know
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingPhase 1City of Hope Medical CenterNCT07278856Written as VincristineHow we know
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07444710Written as VincristineHow we know
- Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLNot yet recruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07921550Written as VincristineHow we know
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")RecruitingPhase 1National Cancer Institute (NCI)NCT07649304Written as Vincristine SulfateHow we know
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091865Written as VincristineHow we know
- Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1City of Hope Medical CenterNCT07914166Written as VincristineHow we know
- A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06630091Written as VincristineHow we know
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT04803201Written as VincristineHow we know
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Vincristine SulfateHow we know
- A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesRecruitingPhase 1Janssen Research & Development, LLCNCT07308132Written as VincristineHow we know
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Not yet recruitingPhase 3AstraZenecaNCT07911553Written as VincristineHow we know
Showing 20 of 447.
As the comparator · 49 — what is tested is compared with Vincristine
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06717347Written as VincristineHow we know
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaRecruitingPhase 3National Cancer Institute (NCI)NCT04166409Written as Vincristine SulfateHow we know
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091254Written as VincristineHow we know
- A Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationRecruitingPhase 2German CLL Study GroupNCT07917780Written as VincristineHow we know
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingPhase 3Ruijin HospitalNCT07719855Written as VincristineHow we know
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingPhase 3The Lymphoma Academic Research OrganisationNCT06006117Written as CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)How we know
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as VincristineHow we know
- Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical StudyRecruitingPhase 2Sun Yat-sen UniversityNCT05457829Written as Temozolomide+Irinotecan+VincristineHow we know
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingPhase 2University of BirminghamNCT05848765Written as VincristineHow we know
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for LymphomaRecruitingPhase 3The Affiliated People's Hospital of Ningbo UniversityNCT06520163Written as CHOPHow we know
- A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's SarcomaNot yet recruitingPhase 2Tang XiaodongNCT07092306Written as Irinotecan Combined with Temozolomide and Vincristine (VIT)How we know
- Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II TrialRecruitingPhase 2Fei LiNCT06700798Written as VincristineHow we know
- Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3ANot yet recruitingPhase 2Sun Yat-sen UniversityNCT06961500Written as CHOPHow we know
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06516978Written as VincristineHow we know
- Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic TumorRecruitingPhase 3Weiguo LvNCT02639650Written as vincristineHow we know
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03871257Written as Vincristine SulfateHow we know
- CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaTerminatedPhase 2Emergent BioSolutionsNCT00893516Written as CHOPHow we know
- Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5Active, not recruitingPhase 3The Lymphoma Academic Research OrganisationNCT06284122Written as VincristinHow we know
- Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell TumorsCompletedPhase 2St. Jude Children's Research HospitalNCT01946529Written as vincristineHow we know
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as VincristineHow we know
Showing 20 of 49.
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
Codes
What other systems call Vincristine · ClinicalTrials.gg INT008409
- MeSH (NLM) D014750VincristineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5J49Q6B70FVINCRISTINEConfirmed FDA, NLM, Wikidata
- RxNorm 11202Confirmed FDA, Wikidata
- Wikidata Q408977vincristineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C933VincristineConfirmed FDA, Wikidata
- DrugBank DB00541One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D014750 | Vincristine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5J49Q6B70F | VINCRISTINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 11202 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408977 | vincristine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C933 | Vincristine | Confirmed FDA, Wikidata |
| DrugBank | DB00541 | — | One source Wikidata |
Also registered as vincristine sulfate (UNII T5IRO3534A · RxNorm 11203).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.